KALYDECOHCP.COM: Keyword Density Checker

Total words: 2696 | 2-word phrases: 691 | 3-word phrases: 798 | 4-word phrases: 849

PAGE INFO

Title	Try to keep the title under 60 characters (49 characters) KALYDECO® (ivacaftor) \| Healthcare Professionals
Description	Try to keep the meta description between 50 - 160 characters (200 characters) Get more information about KALYDECO, including trial data, safety and dosing information, and resources for healthcare professionals. See Important Safety Information and full Prescribing Information.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (115 characters) FOR PATIENTS WITH CYSTIC FIBROSIS AGE 1 MONTH* AND OLDER WITH AT LEAST ONE MUTATION THAT IS RESPONSIVE TO KALYDECO1

#	Keyword	Frequency	Density
1	in patients with	12	1.50%
2	patients with a	10	1.25%
3	have been reported	8	1.00%
4	been reported in	8	1.00%
5	alt or ast	7	0.88%
6	in patients age	7	0.88%
7	of transaminase elevations	7	0.88%
8	history of transaminase	7	0.88%
9	a history of	6	0.75%
10	is responsive to	6	0.75%
11	month and older	6	0.75%
12	with a history	6	0.75%
13	vitro assay data	5	0.63%
14	of kalydeco in	5	0.63%
15	use of kalydeco	5	0.63%
16	potentiation based on	5	0.63%
17	patients genotype is	5	0.63%
18	and older who	5	0.63%
19	1 month and	5	0.63%
20	age 1 month	5	0.63%
21	patients treated with	5	0.63%
22	treated with kalydeco	5	0.63%
23	cystic fibrosis cf	5	0.63%
24	have at least	5	0.63%
25	one mutation in	5	0.63%
26	patients with cf	5	0.63%
27	mutation in the	5	0.63%
28	vertex pharmaceuticals incorporated	5	0.63%
29	transaminase elevations consider	5	0.63%
30	fibrosis cf in	5	0.63%

#	Keyword	Frequency	Density
1	have been reported in	8	0.94%
2	with a history of	6	0.71%
3	patients with a history	6	0.71%
4	one mutation in the	5	0.59%
5	a history of transaminase	5	0.59%
6	month and older who	5	0.59%
7	in patients with a	5	0.59%
8	cystic fibrosis cf in	5	0.59%
9	1 month and older	5	0.59%
10	age 1 month and	5	0.59%
11	in patients with cf	5	0.59%
12	fibrosis cf in patients	4	0.47%
13	cf in patients age	4	0.47%
14	in patients age 1	4	0.47%
15	gene that is responsive	4	0.47%
16	for the treatment of	4	0.47%
17	indicated for the treatment	4	0.47%
18	elevations were more common	4	0.47%
19	were more common in	4	0.47%
20	based on clinical andor	4	0.47%
21	history of transaminase elevations	4	0.47%
22	elevations or in patients	4	0.47%
23	or in patients who	4	0.47%
24	alt and ast should	4	0.47%
25	frequent monitoring of liver	4	0.47%
26	and ast should be	4	0.47%
27	ast should be assessed	4	0.47%
28	that is responsive to	4	0.47%
29	of transaminase elevations consider	4	0.47%
30	initiating kalydeco every 3	4	0.47%
31	and annually thereafter for	4	0.47%
32	at least one mutation	4	0.47%
33	the first year of	4	0.47%
34	during the first year	4	0.47%
35	patients age 1 month	4	0.47%
36	months during the first	4	0.47%
37	in vitro assay data	4	0.47%
38	cyp3a inducers such as	4	0.47%
39	patients treated with kalydeco	4	0.47%
40	potentiation based on clinical	4	0.47%

#	URL	Whois	Check
1	https://pi.vrtx.com/files/uspi_ivacaftor.pdf	Whois	vrtx.com
2	https://www.kalydeco.com/	Whois	kalydeco.com
3	https://www.vertexgps.com/how-to-enroll-patients	Whois	vertexgps.com
4	https://www.kalydeco.com/	Whois	kalydeco.com
5	https://www.vertexgps.com/how-to-enroll-patients	Whois	vertexgps.com
6	https://www.vertexgps.com/	Whois	vertexgps.com
7	http://pi.vrtx.com/files/uspi_ivacaftor.pdf	Whois	vrtx.com
8	https://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf	Whois	vrtx.com
9	https://vrtx.com	Whois	vrtx.com
10	https://www.vrtx.com/about-us/	Whois	vrtx.com
11	https://www.vrtx.com/english-privacy-us-residents	Whois	vrtx.com
12	https://www.vrtx.com/terms-and-conditions	Whois	vrtx.com
13	http://www.vrtx.com/about-us/contact-us	Whois	vrtx.com
14	https://www.vertexgps.com/how-to-enroll-patients	Whois	vertexgps.com
15	https://www.vertexgps.com/how-to-enroll-patients	Whois	vertexgps.com
16	https://www.vrtx.com	Whois	vrtx.com